Senate Bill S.4031 Signal a Federal Turn Toward Psychedelic Medicine

Senate Bill S.4031 would shift federal psychedelic research into a VA focused healthcare framework by creating Innovative Therapies Centers of Excellence. The bill would establish specialized VA research and treatment centers to study therapies for PTSD, traumatic brain injury, depression, substance use disorders, and chronic pain. It specifically names MDMA, psilocybin, ibogaine, ketamine, and 5-MeO-DMT as compounds under study. The core mechanism is evidence generation, not immediate patient access. The proposal does not address drug scheduling or DEA oversight, and it does not resolve regulatory barriers, but it would fund and require internal data systems, standardized protocols, clinician training, centralized data collection, and coordinated multi site trials. S.4031 was referred to the Senate Committee on Veterans' Affairs on March 9, 2026, and its future depends on committee movement and coordination with the House companion measure, H.R. 2623. The editors note adds that the legislation later confirmed at least one VA center requirement and $30 million in annual funding.